Baird raised the firm’s price target on Oscar Health (OSCR) to $19 from $15 and keeps a Neutral rating on the shares. The firm updated its model following strong Q1 results but awaiting clarity on Exchange Risk Adjustment.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OSCR: